Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Neurology

Journal Scan / Research · November 21, 2024

Efficacy and Safety of Xanomeline–Trospium Chloride in Patients With Schizophrenia

JAMA Psychiatry

 

Additional Info

JAMA Psychiatry
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial
JAMA Psychiatry 2024 Aug 01;81(8)749-756, I Kaul, S Sawchak, DP Walling, CA Tamminga, A Breier, H Zhu, AC Miller, SM Paul, SK Brannan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading